Diabetic Macular Edema Market Research
What is Diabetic Macular Edema (DME)?
Diabetic macular edema happens as a result of another eye condition that can develop in people with diabetes called diabetic retinopathy (DR). DME may lead to vision problems or even blindness if left untreated. Retinal thickening caused by the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers can cause swelling (edema). DME can be present with any level of diabetic retinopathy. Close monitoring and intervention at the early stages of DME can lead to better outcomes. Newer therapies, including gene therapies, offer potential new targets for treatment.
Spherix Global Insights – Ophthalmology – Diabetic Macular Edema (DME)
Spherix’s Ophthalmology team covers the Diabetic Macular Edema (DME) market in our RealTime Dynamix™, Launch Dynamix™, Patient Chart Dynamix™, and Special Topix™ services. Spherix’s has the following studies publishing this year covering Diabetic Macular Edema (DME):
- RealTime Dynamix™: Diabetic Macular Edema (DME)
- Launch Dynamix™: Vabysmo (Roche/Genentech) (US)
- Launch Dynamix™: Cimerli (Coherus BioSciences) Ranibizumab Biosimilar (US)
- Launch Dynamix™: Eylea HD in Diabetic Macular Edema (US)
- Patient Chart Dynamix™: Treatment Switching in Diabetic Macular Edema (DME) (US)
- Special Topix™: Ophthalmology Biosimilars Today and Tomorrow (US)
*Pending approvals and launch
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports includes promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Spherix’s RealTime Dynamix™ service includes US quarterly deep dive reports. Core content is supplemented with new variables each wave to provide both tracking of KPIs and an infusion of fresh market-driven insights.
Spherix’s Patient Chart Dynamix™ service includes patient-level data detailing clinical and non-clinical patient demographics, along with rationale for treatment choices. It reveals real patient management patterns through rigorous analysis of large-scale physician report patient chart audits.
Spherix’s Special Topix™ service is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.
Follow Spherix Ophthalmology on Social Media
Follow us for ophthalmology industry news, insights & analysis:
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:
Franchise Leader, Ophthalmology
Email: [email protected]